QNRX:NASDAQQuoin Pharmaceuticals, Ltd. Analysis

Quoin Pharmaceuticals trades well below its long‑term moving averages, with the price hovering near the lower bound of its 52‑week range and a bearish trend indicated by the short‑term moving average lying above the market price. The relative strength index sits in a neutral zone while the MACD histogram shows a modest bullish divergence, suggesting limited short‑term upside but no clear reversal. Volume has been on a downtrend, amplifying liquidity concerns, and the stock exhibits extreme volatility and a highly negative beta, reflecting its sensitivity to market swings.
The company’s pipeline received a material catalyst this week with the filing of an IND for QRX003 in a new indication, which could broaden its clinical prospects. Despite a cash position that comfortably exceeds its modest debt load, the firm reports no revenue, negative earnings and cash burn, placing it firmly in the speculative biotech category where regulatory outcomes dominate valuation.